H1拮抗剂阿司咪唑治疗慢性变应性鼻炎的疗效
Efficacy of an H1 antagonist, astemizole, for chronic allergic rhinitis.
作者信息
Wilson W R, Moss J, Joseph M, Laird N, Glinsiki M
出版信息
Am J Otolaryngol. 1987 May-Jun;8(3):157-60. doi: 10.1016/s0196-0709(87)80039-x.
Astemizole, a new histamine H1 receptor antagonist, was tested in a double-blind cross-over comparison study with chlorpheniramine maleate, a very effective conventional H1 antagonist, in patients with chronic allergic rhinitis. Astemizole was found to be equally effective, yet there was a significant decrease in the side effects of sleepiness (P less than .01) and dry mouth (P less than .05). Astemizole has a completely different structure and binding curves from terfenadine. It is approved for clinical use in the United Kingdom, Canada, and many European countries.
阿司咪唑是一种新型组胺H1受体拮抗剂，在一项双盲交叉对照研究中，与非常有效的传统H1拮抗剂马来酸氯苯那敏对慢性变应性鼻炎患者进行了测试。结果发现阿司咪唑具有同等疗效，但其嗜睡（P<0.01）和口干（P<0.05）等副作用显著减少。阿司咪唑与特非那定的结构和结合曲线完全不同。它已在英国、加拿大和许多欧洲国家获批用于临床。
Zotero 插件